Kynurenate Test · Dried Urine

Your body breaks down tryptophan, the amino acid from protein in your diet, through several different routes. One of those routes produces kynurenic acid, a molecule that quietly shapes how your nerves fire, how your immune system reacts, and how your blood vessels respond to stress.

Measuring kynurenate (kynurenic acid) in dried urine gives you a window into this pathway. It is a research-grade marker without standardized clinical cutpoints, but the patterns it shows can hint at inflammation, mood biology, and metabolic balance that routine bloodwork rarely captures.

What This Molecule Actually Does

Kynurenate (kynurenic acid) is a tryptophan-derived metabolite, meaning a small molecule produced when your cells process the protein building block tryptophan. It is made by a family of enzymes (called kynurenine aminotransferases) inside many tissues, including blood vessel lining cells, immune cells, skeletal muscle, heart, pancreas, and, in the brain, support cells called astrocytes.

On the nerve side, kynurenate dampens excitatory signaling by blocking NMDA receptors, the same receptors that overactive glutamate uses to damage neurons. On the immune side, it activates two receptors (GPR35 and the aryl hydrocarbon receptor) that turn down inflammation and quiet a damage-sensing complex called the NLRP3 inflammasome. Even small shifts in kynurenate can change how much glutamate, dopamine, and acetylcholine your nerves release.

Why It Matters: The Big Picture

Kynurenate sits at a fork in the road. When your body breaks down tryptophan through the kynurenine pathway, it can swing toward making kynurenate (which is calming and protective) or toward making quinolinic acid (which is excitatory and damaging). The balance, often measured as the kynurenate-to-quinolinic-acid ratio, tracks closely with how inflammation is reshaping your nervous system and metabolism.

This is not a yes-or-no number. The same molecule can be protective in one tissue and disruptive in another, which is why interpretation depends on context and trend more than a single reading.

Mood and Depression

In major depressive disorder and bipolar disorder, kynurenate in peripheral blood tends to run lower than in healthy people, and the kynurenate-to-quinolinic-acid ratio shifts toward the damaging side. In one study of adults with depression, kynurenate at a plasma cutoff of 15.48 ng/mL distinguished people with depression from healthy controls with an overall accuracy of about 82.5%.

Lower kynurenate before starting treatment has also been linked to a better response to the antidepressant escitalopram. That makes it a candidate marker not just for the presence of depression but for how someone might respond to specific therapy.

Brain Aging and Alzheimer's Disease

In a study of 416 people, those with higher kynurenic acid in their cerebrospinal fluid (the liquid that bathes the brain) had slower clinical progression of Alzheimer's disease. The interpretation is that the brain ramps up kynurenate as an adaptive, protective response, not that more kynurenate causes the disease.

Reviews of Alzheimer's, Parkinson's, and Huntington's disease consistently describe an imbalance: the brain shifts away from the protective kynurenate branch toward the more toxic quinolinic acid branch. Whether boosting kynurenate slows these diseases is still being studied.

Schizophrenia: A Counterintuitive Finding

In schizophrenia, the pattern flips. Brain levels of kynurenate are elevated, and a recent study in 184 people with first-episode psychosis found that higher serum kynurenic acid predicted poorer response to antipsychotic medication. Too much kynurenate in the wrong place appears to blunt NMDA receptor signaling enough to worsen attention and cognition.

This is not a paradox so much as a phenotype indicator. Kynurenate is not a simple "higher is better" or "lower is worse" marker. It signals how the kynurenine pathway is being rebalanced, and different rebalancing patterns map to different conditions. Depression and Alzheimer's tend to come with relative kynurenate deficits, while subsets of schizophrenia and psychosis come with relative excess. Reading the number requires reading the context.

Heart and Metabolic Health

The broader kynurenine pathway is active in your heart and blood vessels. In a study of people with type 2 diabetes, higher plasma kynurenic acid was associated with a slower decline in kidney function, hinting at a protective role in diabetic kidney disease. A separate study in 1,393 people with heart failure found that elevated plasma kynurenines (the broader pathway, not kynurenate specifically) predicted higher mortality.

In prepubertal children, higher plasma kynurenine pathway metabolites were associated with obesity and a worse metabolic profile, including markers of fatty liver. The pathway acts as a sensor of systemic inflammation, which is why it tracks with cardiometabolic risk.

Inflammation, Infection, and Gut Health

During severe infection, the kynurenine pathway gets switched on hard by immune signaling. In COVID-19, kynurenine above 4.82 nmol/L predicted 90-day death with 82% sensitivity and 72% specificity, and elevated levels also tracked with Long-COVID symptoms. In inflammatory bowel disease, lower intestinal kynurenate is linked to more severe colitis, and restoring kynurenate is protective in human-derived gut tissue research.

This is why a single elevated reading during or shortly after illness should not be treated as a baseline. The pathway is one of your body's stress responders, and it stays elevated for weeks after immune activation.

Reference Ranges

There are no universally accepted clinical cutpoints for urinary kynurenate. The values below come from research and diagnostic studies and are illustrative orientation, not targets. Your own lab will report results in its own units, and absolute numbers vary widely by assay (typically liquid chromatography-mass spectrometry) and specimen type. Compare your results within the same lab over time.

Because kynurenate measurement is still considered exploratory, do not treat any single number as a verdict. A research-derived threshold from a depression study cannot tell you whether your level is "healthy" if you do not have depression. The value of testing is in following your own trend.

Tracking Your Trend

A single kynurenate reading captures one moment in a system that responds to inflammation, sleep, stress, and recent illness. Acute infection alone can shift the pathway for weeks. Tracking the number over time, especially alongside markers of inflammation, gives you a clearer signal than any one snapshot.

A reasonable cadence: get a baseline now, retest in 3 to 6 months if you are making meaningful changes to diet, exercise, sleep, or stress, and then at least annually to watch the trajectory. If you have just been through a major illness or surgery, wait at least 4 to 6 weeks before drawing conclusions from a result.

When Results Can Be Misleading

• Recent illness or infection: acute immune activation, including viral infections like COVID-19, drives kynurenine pathway metabolites up for weeks. A reading during or shortly after illness reflects the immune response, not your baseline.
• Recent intense exercise: in studies of ultramarathon runners and exercise trials, the kynurenine pathway shifts transiently after acute exertion. Avoid testing within 24 to 72 hours of a vigorous workout if you want a steady-state reading.
• Kidney function: kynurenate and related metabolites are cleared in part through the kidneys. Significantly reduced kidney function can raise circulating levels independently of any neurologic or immune process.
• Lab-to-lab variation: assay methods differ across labs and have not been harmonized for kynurenate. Compare your readings within the same lab using the same assay.

What to Do With an Abnormal Result

Because clinical cutpoints are not yet standardized, an out-of-range kynurenate reading is a signal to investigate, not a diagnosis. The most useful next steps depend on the rest of your picture. Pair the result with markers of systemic inflammation (high-sensitivity C-reactive protein), kidney function (eGFR, cystatin C), and metabolic health (fasting insulin, HbA1c). If you have neurologic or mood symptoms, a discussion with a neurologist or psychiatrist who tracks metabolomics is warranted.

If your number is unusually low alongside symptoms of low mood or fatigue, retest in 6 to 8 weeks after reviewing sleep, stress, and inflammation drivers. If your number is unusually high alongside elevated inflammation markers, look for an underlying inflammatory or infectious driver. A pattern of changing values matters more than any one outlier.